Harry H. Yoon, MD, MHS | Authors


HER2 in Esophagogastric Adenocarcinoma

October 24, 2013

Determination of HER2 status has become an important part of the workup of patients with advanced esophagogastric cancer, given recent data from a phase III trial (ToGA) indicating that trastuzumab, an anti-HER2 monoclonal antibody, prolongs survival in these patients.